6 hours ago
1
Nemes Laszlo
SELLAS Life Sciences (NASDAQ:SLS) traded higher in the premarket on Tuesday after the New York-based biotech said that a Phase 2 trial that tested its antitumor agent SLS009 (tambiciclib) as part of a combination regimen for acute myeloid leukemia met all
English (US) ·